PrEP-3D package for Risk Reduction

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Bridge HIV, San Francisco Department of Public Health, San Francisco, CA
Risk Reduction+3 More
PrEP-3D package - Behavioral
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

The PrEP 3D randomized controlled trial (RCT) will study the effectiveness of the PrEP-3D app compared to standard of care for starting pre-exposure prophylaxis (PrEP), continuing PrEP, and adherence to PrEP.

Eligible Conditions

  • Adherence, Medication
  • Risk Reduction
  • HIV, Prevention
  • Pre-Exposure Prophylaxis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 12 months

12 months
Effectiveness of PREP-3D on PREP use

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

PrEP-3D
1 of 1
Experimental Treatment

150 Total Participants · 1 Treatment Group

Primary Treatment: PrEP-3D package · No Placebo Group · N/A

PrEP-3D
Behavioral
Experimental Group · 1 Intervention: PrEP-3D package · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
Closest Location: Bridge HIV, San Francisco Department of Public Health · San Francisco, CA
Photo of San Francisco 1Photo of San Francisco 2Photo of San Francisco 3
2018First Recorded Clinical Trial
2 TrialsResearching Risk Reduction
5 CompletedClinical Trials

Who is running the clinical trial?

Public Health Foundation Enterprises, Inc.Lead Sponsor
12 Previous Clinical Trials
1,358 Total Patients Enrolled
3 Trials studying Risk Reduction
522 Patients Enrolled for Risk Reduction
San Francisco Department of Public HealthOTHER_GOV
33 Previous Clinical Trials
33,891 Total Patients Enrolled
3 Trials studying Risk Reduction
522 Patients Enrolled for Risk Reduction
Alto PharmacyUNKNOWN
Susan Buchbinder, MDPrincipal InvestigatorBridge HIV, San Francisco Department of Public Health
4 Previous Clinical Trials
624 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be between the ages of 18 and 50 years.
You are assigned male at birth and report sex with persons assigned male at birth.
You are interested in taking daily TDF/FTC or TAF/FTC PrEP.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.